On top of all that, at the end of 2025, in its bid to expand image, video, animation, motion design, and VFX creation and ...
Thousands more people with advanced bowel cancer to benefit as NICE approves bevacizumab biosimilars
We’re delighted that NICE has approved bevacizumab for first- and second-line treatment in combination with chemotherapy for advanced bowel cancer patients in England and Wales, following a similar ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback